Xigduo▼ (Dapagliflozin/Metformin) now Authorised in Ireland for Adults with Type 2 Diabetes

Download PDF                                        Forxiga▼ (dapagliflozin) was launched in Ireland in April 2014 and was the first medicine in the SGLT2 inhibitor class to gain marketing authorisation for the treatment of type 2 diabetes. AstraZeneca Pharmaceuticals (Ireland) Ltd is pleased to announce that Xigduo, which combines dapagliflozin and metformin in one tablet, is now available in Ireland. It is the first fixed-dose combination of an SGLT2 inhibitor and metformin to gain marketing authorisation, combining two anti-hyperglycaemics with complementary and distinct mechanisms of action. Xigduo is indicated as a twice-daily oral medication to improve glycaemic control in adults with type 2 diabetes.…